McCoy to Leave J&J, Gorsky Prepares to Take Over

Article

Johnson & Johnson announced this week that Sheri S. McCoy, vice-chairman of the Executive Committee, has resigned from the company. She was considered to be in line for the CEO position.

Johnson & Johnson announced this week that Sheri S. McCoy, vice-chairman of the Executive Committee, has resigned from the company. She was considered to be in line for the CEO position, being filled by Alex Gorsky.

McCoy, who joined J&J in 1982, is reportedly moving on to head Avon, a smaller company in comparison to J&J but with similar healthcare products in the cosmetic and skincare area.

“Sheri has made important contributions across Johnson & Johnson throughout her career. During these last several years, she was instrumental in helping to bring stronger strategic focus to our Pharmaceutical business as it builds a robust pipeline and launches important new medicines; and to our Consumer business as it leverages the success of its iconic brands and worked to resolve some recent challenges,”
 said J&J CEO and Chairman William C. Weldon, in a company statement.

J&J announced earlier this year that Gorsky would be succeeding Weldon, effective with the April 2012 annual shareholders’ meeting. Weldon served as Chairman and CEO since 2002. Gorsky is currently vice-chairman of the company’s Executive Committee with responsibility for the Medical Devices & Diagnostics Group, Global Supply Chain, Health Care Compliance & Privacy, and Government Affairs & Policy. Weldon will remain chairman of the company’s board of directors.


Comment from Reader J. Coupal, Lexington, KY:

"'..and to our Consumer business as it leverages the success of its iconic brands and worked to resolve some recent challenges.' '..[R]esolve some recent challenges' is the understatement of the year. A wide variety of seemingly unsolvable quality problems with McNeil Consumer products reflects performance of senior management responsible for quality oversight.It will take years for the public to regain enough confidence to buy and take those iconic products."

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content